Literature DB >> 18611792

Oxacillin susceptibility of coagulase-negative staphylococci: role for mecA genotyping and E-test susceptibility testing.

N Cimolai1, C Trombley, A Zaher.   

Abstract

For 115 clinical isolates of coagulase-negative staphylococci which were acquired from 100 patients, we compared the results of routine critical agar dilution susceptibility testing (4% NaCl, 6 mg/ml oxacillin) with mecA gene detection by a polymerase chain reaction amplification. Discrepant results were subsequently reassessed with critical agar dilution testing, repeat mecA genotyping, disc radial diffusion susceptibility testing, E-test and determination of beta-lactamase status. For the initial comparisons, 36 isolates were susceptible and lacked mecA whereas 54 isolates were resistant and had evidence of mecA. Among 17 mecA positive/agar dilution susceptible bacteria, four were clearly resistant by E-test, one isolate had borderline resistance (MIC, 2-4 mg/l), and 12 were resistant when E-test was applied to resistant subpopulations. Initial E-tests facilitated the recognition of the heteroresistant isolates. For eight mecA negative/agar dilution resistant isolates, two were confirmed as oxacillin susceptible and six were mecA positive upon retesting. Although 53.9% had been classified initially as resistant by agar dilution, 67.0% were finally deemed resistant. Critical agar dilution underestimates oxacillin resistance among coagulase-negative staphylococci, and accurate detection of resistance is facilitated by mecA genotyping and E-test.

Entities:  

Year:  1997        PMID: 18611792     DOI: 10.1016/s0924-8579(96)00363-9

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  1 in total

1.  Antistaphylococcal β-Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis.

Authors:  M Carugati; C A Petti; C Arnold; J M Miro; J M Pericàs; C Garcia de la Maria; Z Kanafani; E Durante-Mangoni; J Baddley; D Wray; J L Klein; F Delahaye; N Fernandez-Hidalgo; M M Hannan; D Murdoch; A Bayer; V H Chu
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.